BioSpace News Archive

SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended June 30, 2022.

Calithera Biosciences, Inc., a clinical-stage, precision-oncology biopharmaceutical company, announced its financial results for the second quarter ended June 30, 2022.

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), today reported financial results for the second quarter ended June 30, 2022, and highlighted recent corporate accomplishments, including the selection of a lead development candidate from its SENTI-202 program with an anticipated Investigational New Drug (IND) application in 2023.

Viridian Therapeutics, Inc., a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, announced that it has commenced an underwritten public offering of $175 million of shares of its common stock and series B preferred stock.

Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 2, 2022.

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2022.

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), today reported financial results as of and for the six months June 30, 2022 and operational and commercial highlights for the second quarter.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) (“Ginkgo”), the leading horizontal platform for cell programming, today announced its results for the second quarter ended June 30, 2022.

INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), today announced financial results for the second quarter ended June 30, 2022 and provided a business update.

Inhibrx, Inc. (Nasdaq: INBX), today announced that the European Commission (“EC”), based on a positive opinion issued by the European Medicines Agency (“EMA”), has granted orphan medicinal product designation to INBRX-109 for the treatment of chondrosarcoma.